Dynamics of CD19+ B cells in patients with idiopathic MN versus RA versus AAV. Patients with MN were treated with RTX (1 g intravenously) on days 1 and 15 in our previous study (1) and with 375 mg/m2 × 4 on days 1, 8, 15, and 22 in this study. Patients with RA were treated with RTX (1 g intravenously) on days 1 and 15, and patients with AAV received RTX (375 mg/m2 × 4) on days 1, 8, 15, and 22 (1).